Aditxt Announces Closing of $4.25 Million Public Offering
October 20 2021 - 5:31PM
Business Wire
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation
company with a mission to improve the health of the immune system,
announced today the closing of its previously announced
underwritten public offering of 2,833,333 shares of its common
stock at a public offering price of $1.50 per share, for gross
proceeds of $4.25 million, before deducting underwriting discounts
and offering expenses.
Aditxt plans to use a portion of the net of underwriting
discounts proceeds of approximately $3.91 million from this
offering to fund certain obligations under its previously announced
Transaction Agreement with AiPharma Global Holdings entered into on
October 4, 2021.
Revere Securities, LLC acted as sole book-running manager for
the offering. Sheppard, Mullin, Richter & Hampton LLP acted as
counsel to Aditxt and Lucosky Brookman LLP acted as counsel to the
underwriter.
The offering of the common stock described above is being made
pursuant to an effective “shelf” registration statement on Form S-3
(File No. 333-257645), that was previously filed with the
Securities and Exchange Commission ("SEC") and declared effective
by the SEC on July 13, 2021, and the base prospectus contained
therein. The final prospectus supplement and accompanying
prospectus have been filed with the SEC and are available on the
SEC's website located at http://www.sec.gov. Copies of the
prospectus supplement and the accompanying base prospectus relating
to the offering of common stock may be obtained by contacting
Revere Securities, LLC, 650 Fifth Avenue, 35th Floor, NY, NY 10019,
jgiamichael@reveresecurities.com or (917) 710-5515.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Aditxt
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt's immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt's immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of federal securities laws. Forward-looking statements in
this press release include, without limitation, the ability of the
Company to close the offering. Forward-looking statements include
statements regarding the Company's intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product and
business development; the Company's intellectual property position;
the Company's ability to develop commercial functions; expectations
regarding product launch and revenue; the Company's results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section titled "Risk Factors" in the Company's
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company's other filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211020006109/en/
Media and Investor Relations Contact: Aditxt, Inc.
ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024